SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

28 Jul 2025 Evaluate
The company witnessed a 12.19% growth in the revenue at Rs. 12085.60 millions for the quarter ended June 2025 as compared to Rs. 10772.70 millions during the year-ago period.A slim rise of 8.02% was recorded in the Net profit for the quarter ended June 2025 to Rs. 2549.70  millions  From Rs. 2360.30 millions.Operating profit for the quarter ended June 2025 rose to 3700.30 millions as compared to 3442.00 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 12085.60 10772.70 12.19 12085.60 10772.70 12.19 43220.40 39711.20 8.84
Other Income 406.30 283.70 43.21 406.30 283.70 43.21 1198.70 1164.80 2.91
PBIDT 3700.30 3442.00 7.50 3700.30 3442.00 7.50 13245.90 12359.10 7.18
Interest 7.30 7.20 1.39 7.30 7.20 1.39 46.00 68.00 -32.35
PBDT 3693.00 3434.80 7.52 3693.00 3434.80 7.52 13199.90 12291.10 7.39
Depreciation 403.10 329.20 22.45 403.10 329.20 22.45 1399.30 1321.60 5.88
PBT 3289.90 3105.60 5.93 3289.90 3105.60 5.93 11800.60 10969.50 7.58
TAX 740.20 745.30 -0.68 740.20 745.30 -0.68 2631.70 2897.10 -9.16
Deferred Tax 32.90 31.10 5.79 32.90 31.10 5.79 51.40 121.30 -57.63
PAT 2549.70 2360.30 8.02 2549.70 2360.30 8.02 9168.90 8072.40 13.58
Equity 250.70 250.70 0.00 250.70 250.70 0.00 250.70 252.70 -0.79
PBIDTM(%) 30.62 31.95 -4.17 30.62 31.95 -4.17 30.65 31.12 -1.53

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×